Adjuvant Cisplatin and Vinorelbine for Completely Resected Non-small Cell Lung Cancer Subgroup Analysis of the Lung Adjuvant Cisplatin Evaluation. Jean-Yves Douillard, MD, PhD, He´le`ne Tribodet, MSc, Delphine Aubert, MSc, Frances A. Shepherd, MD, Rafael Rosell, MD, PhD, Keyue Ding, PhD, Anne-Sophie Veillard, MSc, Lesley Seymour, PhD, Thierry Le Chevalier, MD, Stephen Spiro, MD,* Richard Stephens, Jean Pierre Pignon, MD, PhD and on behalf of the LACE Collaborative Group. Journal of Thoracic Oncology. Volume 5, Number 2, February 2010

Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB–IIIA non-smallcell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Jean-Yves Douillard, Rafael Rosell, Mario De Lena, Francesco Carpagnano, Rodryg Ramlau, Jose Luis Gonzáles-Larriba, Tomasz Grodzki, Jose Rodrigues Pereira, Alain Le Groumellec, Vito Lorusso, Claude Clary, Antonio J Torres, Jabrail Dahabreh, Pierre-Jean Souquet, Julio Astudillo, Pierre Fournel, Angel Artal-Cortes, Jacek Jassem, Leona Koubkova, Patricia His, Marcello Riggi, Patrick Hurteloup. Lancet Oncol 2006; 7: 719–27

Meta-Analysis of Postoperative Adjuvant Chemotherapy With Tegafur-Uracil in Non–Small-Cell Lung Cancer. Chikuma Hamada, Fumihiro Tanaka, Mitsuo Ohta, Shigefumi Fujimura, Ken Kodama, Munehisa Imaizumi, and Hiromi Wada. J Clin Oncol 23:4999-5006

Randomized Study of Adjuvant Chemotherapy for Completely Resected Stage I, II, or IIIA Non–Small-Cell Lung Cancer. Giorgio V. Scagliotti, Roldano Fossati, Valter Torri, Lucio Crino`, Giuseppe Giaccone, Giovanni Silvano, Massimo Martelli, Maurizia Clerici, Francesco Cognetti, Maurizio Tonato For the Adjuvant Lung Project Italy/European Organisation for Research and Treatment of Cancer–Lung Cancer Cooperative Group Investigators. Journal of the National Cancer Institute, Vol. 95, No. 19, October 1, 2003

Randomized Phase III Trial of Vinorelbine Plus Cisplatin Compared With Observation in Completely Resected Stage IB and II Non–Small-Cell Lung Cancer: Updated Survival Analysis of JBR-10. Charles A. Butts, Keyue Ding, Lesley Seymour, Philip Twumasi-Ankrah, Barbara Graham, David Gandara, David H. Johnson, Kenneth A. Kesler, Mark Green, Mark Vincent, Yvon Cormier, Glenwood Goss, Brian Findlay, Michael Johnston, Ming-Sound Tsao, and Frances A. Shepherd. J Clin Oncol 28:29-34